PMID- 31196912
OWN - NLM
STAT- MEDLINE
DCOM- 20201214
LR  - 20201214
IS  - 1468-2044 (Electronic)
IS  - 0003-9888 (Linking)
VI  - 105
IP  - 10
DP  - 2020 Oct
TI  - Variation in the management of Kawasaki disease.
PG  - 1004-1006
LID - 10.1136/archdischild-2019-317191 [doi]
AB  - Intravenous immunoglobulin (IVIG) reduces coronary aneurysms in patients with 
      Kawasaki disease (KD), but additional management options remain challenging, with 
      no generalisable evidence-based recommendations. We performed a survey of 724 
      physicians from 73 countries to assess variation in practice. IVIG was the 
      preferred initial treatment by 659 (91%) of respondents. Criteria for adjunctive 
      primary treatment varied considerably and definitions of IVIG resistance varied 
      markedly by geographical continent, Human Development Index tiers and medical 
      specialty. A second dose of IVIG was used most often for patients with coronary 
      aneurysm non-responsive to initial treatment (572, 79%), but corticosteroids 
      (379, 52%) and tumour necrosis factor alpha inhibitors (208, 29%) were also 
      frequently used. Our findings highlight the need for international collaborative 
      efforts to optimise management of patients with KD worldwide.
CI  - (c) Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and 
      permissions. Published by BMJ.
FAU - Dionne, Audrey
AU  - Dionne A
AD  - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.
FAU - Burgner, David
AU  - Burgner D
AD  - Department of Paediatrics, Murdoch Children's Research Institute, Parkville, 
      Victoria, Australia.
FAU - De Ferranti, Sarah
AU  - De Ferranti S
AD  - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.
FAU - Singh-Grewal, Davinder
AU  - Singh-Grewal D
AD  - Department of Rheumatology, University of Sydney, Sydney, New South Wales, 
      Australia.
FAU - Newburger, Jane
AU  - Newburger J
AD  - Department of Cardiology, Boston Children's Hospital, Boston, Massachusetts, USA.
FAU - Dahdah, Nagib
AU  - Dahdah N
AD  - Department of Pediatric Cardiology, University of Montreal, Montreal, Quebec, 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190613
PL  - England
TA  - Arch Dis Child
JT  - Archives of disease in childhood
JID - 0372434
RN  - 0 (Glucocorticoids)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Coronary Aneurysm/drug therapy
MH  - Drug Resistance
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Immunoglobulins, Intravenous/therapeutic use
MH  - Immunologic Factors/therapeutic use
MH  - Male
MH  - Mucocutaneous Lymph Node Syndrome/*drug therapy
MH  - Pediatrics
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Surveys and Questionnaires
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
OTO - NOTNLM
OT  - Kawasaki disease
OT  - cardiology
OT  - intravenous immunoglobulin
COIS- Competing interests: None declared.
EDAT- 2019/06/15 06:00
MHDA- 2020/12/15 06:00
CRDT- 2019/06/15 06:00
PHST- 2019/03/08 00:00 [received]
PHST- 2019/04/25 00:00 [revised]
PHST- 2019/05/09 00:00 [accepted]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2020/12/15 06:00 [medline]
PHST- 2019/06/15 06:00 [entrez]
AID - archdischild-2019-317191 [pii]
AID - 10.1136/archdischild-2019-317191 [doi]
PST - ppublish
SO  - Arch Dis Child. 2020 Oct;105(10):1004-1006. doi: 
      10.1136/archdischild-2019-317191. Epub 2019 Jun 13.